pharma · Hypertriglyceridemia · Asthma · GRCE
Grace Therapeutics
Grace Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA
- Employees
- 18
- Programs
- 29
- Drugs
- 37
- Patents
- 34
Grace Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Grace Therapeutics.
Grace Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
GTX-101
Grace Therapeutics
Postherpetic Neuralgia
1 trial -
GTX-102 medium dose fast Period 1 and Period 2
Grace Therapeutics
Ataxia Telangiectasia
1 trial -
GTX-104
Grace Therapeutics
Aneurysmal Subarachnoid Hemorrhage
1 trial -
Hydromorphone
Grace Therapeutics
Pain
1 trial -
Ketamine (Ketalar)
Grace Therapeutics
Pain
1 trial -
Ketamine (Ketalar) Dose Level 1
Grace Therapeutics
Pain, Postoperative
1 trial
Frequently asked questions
How many clinical projects does Grace Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.